Capital Research Global Investors Alnylam Pharmaceuticals, Inc. Transaction History
Capital Research Global Investors
- $463 Billion
- Q3 2024
A detailed history of Capital Research Global Investors transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 5,243,903 shares of ALNY stock, worth $1.28 Billion. This represents 0.31% of its overall portfolio holdings.
Number of Shares
5,243,903
Previous 3,255,648
61.07%
Holding current value
$1.28 Billion
Previous $791 Million
82.33%
% of portfolio
0.31%
Previous 0.18%
Shares
8 transactions
Others Institutions Holding ALNY
# of Institutions
642Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$4.04 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.09 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.34 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.21 Billion0.24% of portfolio
-
Baillie Gifford & CO4.89MShares$1.2 Billion1.03% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...